Amneal Q1 Revenue $723M Up 4%, Specialty Segment Grows 23%
Amneal Pharmaceuticals posted first-quarter net revenue of $723 million, up 4%, with GAAP net income surging 411% to $62 million and diluted EPS of $0.19. Specialty revenue climbed 23%, driving adjusted EBITDA to $202 million and the company reaffirmed full-year guidance of $3.05–3.15 billion revenue and $0.95–1.05 EPS.
1. First-Quarter Financial Results
Amneal posted net revenue of $723 million for Q1 2026, a 4% increase from Q1 2025, with GAAP net income of $62 million compared to $12 million a year earlier. Diluted EPS rose to $0.19 from $0.04.
2. Segment Performance
Specialty segment net revenue increased 23%, led by CREXONT®, BREKIYA® autoinjector and UNITHROID®, while Affordable Medicines revenue grew 2% on women’s health and ADHD portfolios. AvKARE sales declined 4% as government channel growth was offset by weaker distribution margins.
3. Profitability and Margin Expansion
First-quarter adjusted EBITDA reached $202 million, up 19%, reflecting higher revenue and a portfolio shift that expanded gross margin by 750 basis points. Adjusted diluted EPS climbed 29% to $0.27.
4. Full-Year Guidance Affirmed
The company reaffirmed its 2026 guidance of $3.05–3.15 billion in net revenue, $740–770 million in adjusted EBITDA, and $0.95–1.05 in adjusted EPS, with projected operating cash flow of $350–400 million and about $110 million in capital expenditures.